2017
DOI: 10.1373/jalm.2016.022822
|View full text |Cite
|
Sign up to set email alerts
|

Method Validation of Human Chorionic Gonadotropin and α-Fetoprotein in Cerebrospinal Fluid: Aiding the Diagnosis of Intracranial Germ Cell Tumors

Abstract: Background: Our study objective was to validate 2 individual methods to measure α-fetoprotein (AFP) and human chorionic gonadotropin (hCG) in cerebrospinal fluid (CSF) on the Roche cobas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 23 publications
(33 reference statements)
0
4
0
Order By: Relevance
“…Light’s criteria for the determination of transudative vs. exudative effusions rely on measurement of fluid total protein and/or lactate dehydrogenase [22] , and neither of these widely used tests are available as FDA-cleared methods. Likewise, tumor marker detection in body fluids (e.g., hCG or AFP in cerebrospinal fluid [23] ), most toxicology testing by definitive methods (e.g., toxic alcohols, drugs of abuse), and many endocrine tests (e.g., testosterone) are often performed via LDTs. A system in which clinical laboratories are compelled to submit their validation data for routinely available tests for FDA review would likely result in numerous submissions, potentially delaying approval for months or even years.…”
Section: Discussionmentioning
confidence: 99%
“…Light’s criteria for the determination of transudative vs. exudative effusions rely on measurement of fluid total protein and/or lactate dehydrogenase [22] , and neither of these widely used tests are available as FDA-cleared methods. Likewise, tumor marker detection in body fluids (e.g., hCG or AFP in cerebrospinal fluid [23] ), most toxicology testing by definitive methods (e.g., toxic alcohols, drugs of abuse), and many endocrine tests (e.g., testosterone) are often performed via LDTs. A system in which clinical laboratories are compelled to submit their validation data for routinely available tests for FDA review would likely result in numerous submissions, potentially delaying approval for months or even years.…”
Section: Discussionmentioning
confidence: 99%
“…First, the sensitivity and speci city of these markers varies depending on anatomical involvement, subtype of tumor and progression of the disease, with markedly elevated concentrations occurring in less frequent subtypes of GCT [16]. Second, not all immunoassays have been validated for use in CSF [17]. Third, the cut-off values are not well established.…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, not all immunoassays for βhCG have been validated for use in CSF, which can make interpretation difficult. Validations of βhCG in CSF using the Roche Diagnostics Elecsys and Siemens Centaur assays have been published ( 6 , 7 ). Other assays may give no reference range or use serum reference intervals as a guide.…”
Section: Discussionmentioning
confidence: 99%
“…Ideally, it should also include patients with GCT and other pathologies, to calculate sensitivity and specificity, and a measure of stability and interfering factors. The Roche Diagnostics Elecsys assay for CSF βhCG is stable at any temperature for up to 7 days, and does not appear to be influenced by haemolysis or xanthrochromia; however, similar studies of stability were not performed on the Centaur assay ( 6 ). Neither study included sufficient patients with GCT to calculate specificity or sensitivity.…”
Section: Discussionmentioning
confidence: 99%